Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer October 29, 2025
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million October 29, 2025
PROs from VERITAC-2 Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy October 29, 2025
Independent DSMB recommends continuation of pivotal Ph 3 study of Bria-IMT™ + immune CPI in metastatic breast cancer October 25, 2025
VeraMorph Awarded an SBIR Fast Track Grant by NCI Towards Commercialization of the First Effective Oral Fulvestrant Therapy for ER+ Metastatic Breast Cancer October 21, 2025
NMPA approves trastuzumab botidotin (A166) for patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2 therapy October 18, 2025
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement with QIMR Berghofer for a first-in-class PD-L1 degrader program October 16, 2025
TUKYSA Combination Significantly Improves PFS as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial October 16, 2025
Datroway demonstrated statistically significant OS & PFS improvement in 1L metastatic IO-ineligible TNBC patients in TROPION-Breast02 trial October 8, 2025
Supplemental BLA for Adjuvant ENHERTU Followed by THP Accepted in the US for Patients with High-Risk HER2 Positive Early-Stage Breast Cancer October 8, 2025
86% Reduction in Tumor Burden Announced in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen October 7, 2025
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in TNBC September 30, 2025
Enhertu demonstrated statistically significant improvement in invasive DFS vs. T-DM1 in DESTINY-Breast05 Ph III trial in patients with high-risk early breast cancer following neoadjuvant therapy September 30, 2025
Enhertu + pertuzumab granted Priority Review in the US as 1L treatment for patients with HER2-positive metastatic breast cancer September 30, 2025
FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer September 30, 2025
Avenzo Therapeutics Announces $60 Million Series B Financing to support pipeline advancement of oncology drug candidates September 23, 2025
Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant September 23, 2025
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer September 23, 2025
Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti September 23, 2025
Positive Ph 3 Results Show Giredestrant Significantly Improved PFS in ER-Positive Advanced Breast Cancer September 23, 2025
Ph 3 Trial of BNT323/DB-1303 Met Primary Endpoint of PFS in HER2+ve Metastatic or Unresectable Breast Cancer September 10, 2025
HERTHENA-Breast04 Ph 3 Trial of Patritumab Deruxtecan Initiated for Metastatic HR+ve, HER2-neg Breast Cancer Previously Treated with Endocrine Therapy September 3, 2025
